Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Nov 10;6:36599. doi: 10.1038/srep36599

Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease

Hoang Kim Tu Trinh 1,*, Su-Chin Kim 2,*, Kumsun Cho 3, Su-Jung Kim 4, Ga-Young Ban 1, Hyun-Ju Yoo 4, Joo-Youn Cho 3, Hae-Sim Park 1,a, Seung-Hyun Kim 1,2,b
PMCID: PMC5103193  PMID: 27830727

Abstract

Sphingolipid (SL) metabolites have been suggested to be important inflammatory mediators in airway inflammation and asthma. However, little is known about SL metabolites in aspirin-exacerbated respiratory disease (AERD). We aimed to explore the potential AERD biomarkers by conducting lipidomics targeting SL metabolites. The levels of SL metabolites in serum and urine samples from 45 AERD patients and 45 aspirin-tolerant asthma (ATA) patients were quantified through mass spectrometry. During the lysine-aspirin bronchoprovocation test (ASA-BPT), the levels of serum sphingomyelin (SM) were significantly decreased in AERD (P < 0.05) but not in ATA. The serum SM levels were positively correlated with airway responsiveness to methacholine. At the basal status before the ASA-BPT, the levels of serum sphingosine-1-phosphate (S1P) and urine sphingosine were significantly higher in the AERD patients compared with that of ATA patients (P < 0.001) and were positively correlated with a greater decrease in FEV1 (%) values following the ASA-BPT test (P < 0.001 for each), and with serum periostin level (P < 0.05 for each). This study is the first to evaluate serum S1P and urine sphingosine as potential biomarkers of AERD as well as to examine the metabolic disturbance of SL in AERD patients.

Sphingolipids (SLs) are ubiquitous cell membrane components that regulate multiple cellular processes, such as cell division, differentiation, apoptosis and autophagy1,2. The metabolism of SL is a complex pathway that generates sphingosine-1-phosphate (S1P) from various precursors, using ceramide as a backbone. Ceramide is produced from either de novo SL synthesis or sphingomyelin (SM)3. Ceramide is deacetylated by ceramidases to produce sphingosine, which is then phosphorylated by sphingosine kinase types 1 and 2, producing S1P3.

The potential roles of SL metabolites in respiratory diseases have been discussed, although there is some debate4,5. Acid sphingomyelinase, an enzyme of SM hydrolysis, is involved in endothelial dysfunction, cytokine responses and neutrophils sequestration during acute lung injury5. Decreased serine palmitoyl-CoA transferase (SPT) activity is associated with methacholine-induced airway hyperreactivity6. Ceramide expression has been detected in patients with emphysema and chronic-obstructive pulmonary disease7.

Previous studies linking asthma to SL have focused on airway inflammation and allergic responses related to S1P. S1P can initiate mast cell activation and chemotaxis as well as amplify mast cell degranulation by interacting with S1P receptors, primarily S1P1 and S1P28,9. An in vivo study has reported that S1P treatment induced secretion of T-helper 2 lymphocyte (Th2) and Th17 cytokines, such as interleukin-4 (IL-4) and IL-17, respectively10. S1P has also been associated with methacholine-induced airway hyperreactivity, bronchoconstriction and airway remodeling by targeting genes regulating cell proliferation4,11,12.

Asthma is a common and clinically heterogeneous disorder that is characterized by intermittent airflow obstruction, airway hyperreactivity, chronic airway inflammation, and increased mucus production13. Because of its heterogeneity, asthma is hard to explain by a single mechanism. Lotvall et al. have introduced the definition “endotype” to define different asthma subtypes, based on their mechanisms14. Asthma could be classified into six endotypes (depending on the disease characteristics), including aspirin-exacerbated respiratory disease (AERD) and aspirin-tolerant asthma (ATA). AERD, also termed “aspirin sensitive asthma”, is a syndrome triggered by ingesting non-steroidal anti-inflammatory drugs (NSAIDs) that is associated with an increased production of cysteinyl leukotrienes (CysLTs). AERD is likely to be a more severe case of asthma, with a higher frequency of emergency visits/hospitalizations and increased mortality versus allergic asthma15,16,17. However, we still lack good biomarkers to differentiate AERD from ATA.

Given that SLs, particularly S1P, could contribute to the pathogenesis of airway inflammation and asthma, we aimed to investigate the SL profiles of AERD patients and its association with clinical outcomes. The serum and urine samples from AERD and ATA patients were analyzed for SL metabolites using lipid chromatograpy- mass spectrometry. Additionally, we searched for a correlation between SL metabolites and key AERD biomarkers, 15-hydroxyeicosatetraenoic acid (15-HETE)18, human leukocyte antigen HLA-DBP1*030119, cysteinyl leukotriene receptor type 1 (CYSLTR1) gene polymorphism20 and periostin21. To discriminate AERD from ATA, receiver operating characteristics (ROC) curve analysis for serum S1P and urine sphingosine were analyzed.

Results

Patient characteristics

Table 1 shows the clinical characteristics of the study subjects. The AERD patients showed a greater decrease in FEV1 (%) following the Lysine-Aspirin bronchoprovocation test (ASA-BPT) than the ATA patients (P < 0.001). The AERD patients were younger than the ATA patients (P = 0.045). The AERD patients showed a larger decline in FEV1 (%) predicted values following the ASA-BPT and a lower PC20 value than the ATA patients (P < 0.001 and P = 0.004, respectively). The AERD patients had higher frequencies of rhinosinusitis and nasal polyposis compared with the ATA patients (86.7% vs. 61.9%, P = 0.013 and 37.8% vs 16.7%, P = 0.033, respectively). There were no significant differences between the AERD and ATA patients in terms of the other baseline characteristics.

Table 1. Clinical demographics of the study subjects.

  AERD ATA P value
(N = 45) (N = 45) AERD vs ATA
Age (year) 40.27 ± 13.43 (16–69) 46.07 ± 18 (18–74) 0.045
Sex (Female) 28 (62.2%) 32 (71.1%) 0.371
Atopy 26 (57.8%) 17 (38.6%) 0.071
Total IgE (KU/L)* 2.31 ± 0.57 2.06 ± 0.65 0.458
Baseline FEV1 (% Pred) 84.65 ± 17.94 85.84 ± 16.55 0.79
% Fall (FEV1)§ 22.57 ± 10.19 4.67 ± 3.56 <0.001
PC20 (mg/mL)* 0.25 ± 0.67 0.69 ± 0.55 0.004
Rhinosinusitis 39/45 (86.7%) 26/42 (61.9%) 0.013
Nasal polyposis 16/45 (37.8%) 7/42 (16.7%) 0.033
Open in a new tab

AERD, aspirin-exacerbated respiratory disease; ATA, aspirin- tolerant asthma; NA, not applicable. The continuous data are presented as the means ± SD. The dichotomous data are presented as numbers (%). The data were analyzed with the t test and Pearson’s chi-squared test.

§The percent of FEV1 decreased during the ASA-BPT. Values in bold indicate significant P value.

*Log-transformed data were presented and analyzed with the t test.

Correlation of the serum SM levels with methacholine-induced airway hyperreactivity

The serum and urine SL compositions for the AERD and ATA patients during the ASA-BPT are provided in Table 2. To determine how SL metabolites changed following the ASA-BPT, we used star and symbol plotting to consider the induction fold of SL metabolites following the ASA-BPT in the AERD and ATA groups (Fig. E1). The SL profiles of the AERD group showed distinct patterns compared with those of the ATA group. Distorted increased patterns of ceramides and SMs after the ASA-BPT were characteristic for the ATA group, while decreased patterns of ceramides and SMs were observed in the AERD group following the ASA-BPT.

Table 2. Sphingolipid composition of patients with AERD and ATA before and after the ASA-BPT.

Type of sample SL metabolites Before
 P value† AERD vs ATA After
 P value† AERD vs ATA AERD ATA
AERD (N = 45) ATA (N = 45) AERD (N = 45) ATA (N = 45) P value‡ before vs after P value‡ before vs after
Serum (ng/mL) S1P 101.86 ± 23.48 85.69 ± 20.76 0.001 112.62 ± 20.50 95.71 ± 16.64 <0.001 0.022 0.026
  Sphingosine 4.23 ± 6.66 1.47 ± 1.13 0.009 3.24 ± 3.53 1.58 ± 1.21 0.004 0.053 0.286
  C16:0 Ceramide 56.48 ± 47.92 46.02 ± 40.02 0.391 41.72 ± 35.71 39.39 ± 31.36 0.773 0.129 0.347
  C18:0 Ceramide 596.9 ± 426.14 561.39 ± 458.85 0.753 459.31 ± 471.8 698.98 ± 690.07 0.091 0.189 0.258
  C18:1 Ceramide 26.16 ± 23.32 17.89 ± 14.33 0.096 19.7 ± 16.23 21.45 ± 14.5 0.600 0.182 0.284
  C20:0 Ceramide 431.63 ± 289.19 425.25 ± 334.92 0.856 401.64 ± 437.73 528.77 ± 451.32 0.323 0.725 0.236
  C24:0 Ceramide 43487.36 ± 68722.91 46939.51 ± 65163.38 0.872 28827.32 ± 31166.87 45757.38 ± 46134.42 0.111 0.135 0.905
  C24:1 Ceramide 16428.46 ± 22695.26 14179.54 ± 19020.02 0.469 13063.48 ± 17229.03 15799.6 ± 15430.6 0.565 0.225 0.443
  SM (d18:0/16:0) 634689.34 ± 834083.29 574655.49 ± 496300.08 0.478 418167.27 ± 373508.9 589256.12 ± 543663.91 0.243 0.050 0.887
  SM (d18:0/18:0) 117147.07 ± 100604.79 119072.53 ± 112764.54 0.758 87509.14 ± 57956.94 118776.79 ± 93683.63 0.235 0.035 0.990
  SM (d18:0/18:1) 288429.15 ± 334236.26 251856.35 ± 230136.98 0.346 196502.31 ± 162071.74 254202.24 ± 186918.08 0.348 0.038 0.962
  SM (d18:0/24:0) 229334.6 ± 239649.44 192279.45 ± 160687.77 0.237 156231.31 ± 129139.24 199692.37 ± 163019.24 0.417 0.028 0.813
  SM (d18:0/24:1) 401790.38 ± 393446.33 300081.46 ± 261921.51 0.170 266693.65 ± 207376.38 318932.87 ± 278792.52 0.469 0.013 0.745
  Lyso SM 1348.72 ± 1637.08 1040.93 ± 849.71 0.239 908.74 ± 716.62 1135.74 ± 955.2 0.341 0.060 0.606
Urine* S1P 34.19 ± 9.86 34.66 ± 12.43 0.629 41.19 ± 1.19 1 40.32 ± 0.32 6 0.726 0.001 0.005
(pmol/mg Cr) Sphingosine 48.72 ± 21.58 31.29 ± 13.66 <0.001 50.11 ± 0.11 8 30.16 ± 0.16 1 <0.001 0.532 0.264
  C14:0 Ceramide 154.67 ± 54.67 1 166.96 ± 66.96 9 0.596 144.98 ± 44.98 242.02 ± 42.02 6 0.355 0.424 0.684
  C16:0 Ceramide 2807.85 ± 3699.32 3304.29 ± 5801.60 0.446 2932.36 ± 3180.57 5292.69 ± 9283.27 0.342 0.335 0.234
  C18:0 Ceramide 399.31 ± 38.46 471.51 ± 86.96 0.524 420.10 ± 95.74 839.06 ± 517.83 0.274 0.437 0.151
  C20:0 Ceramide 650.46 ± 16.87 601.17 ± 305.52 0.725 726.95 ± 49.77 916.92 ± 80.26 0.534 0.275 0.178
  C24:0 Ceramide 1861.21 ± 1965.82 2214.40 ± 3925.29 0.340 1962.82 ± 1545.23 3864.77 ± 7114.12 0.193 0.281 0.137
  C24:1 Ceramide 343.32 ± 95.64 726.78 ± 381.57 0.058 378.00 ± 60.49 1215.88 ± 3931.01 0.250 0.239 0.314
  Sphinganine 1184.94 ± 03.38 464.92 ± 0.14 0.072 1255.57 ± 2057.80 725.73 ± 1036.23 0.214 0.513 0.049
  SM (d18:0/16:0) 102343.59 ± 64388.97 97934.29 ± 92854.80 0.662 105220.51 ± 58546.58 111780.95 ± 85951.83 0.593 0.457 0.144
  SM (d18:0/18:0) 24703.85 ± 24562.57 25473.65 ± 32979.63 0.259 23060.26 ± 16354.33 35243.73 ± 47199.35 0.216 0.900 0.143
  SM (d18:0/18:1) 1672.54 ± 1431.48 2409.25 ± 4176.42 0.221 1634.46 ± 1088.91 4708.95 ± 14959.42 0.248 0.673 0.248
  SM (d18:0/24:0) 82282.05 ± 65291.75 75552.38 ± 69356.22 0.719 79694.87 ± 43651.90 96132.00 ± 80454.76 0.351 0.661 0.074
  SM (d18:0/24:1) 40989.74 ± 38049.69 40254.86 ± 46033.41 0.450 38362.31 ± 24894.45 53031.24 ± 66543.38 0.224 0.863 0.115
Open in a new tab

AERD, aspirin-exacerbated respiratory disease; ATA, aspirin- tolerant asthma;, SM, sphingomyelin; Cr, creatinine.

*C14 Ceramide and sphinganine were not detected in human serum samples.

†P value was calculated by GLM, controlling for sex and age. Values in bold indicate significant P value.

‡P value was calculated using a paired t-test.

Comparing changes in the SL metabolite levels during the ASA-BPT, the levels of serum SMs (d18:0/18:0, d18:0/18:1, d18:0/24:0, d18:0/24:1) were significantly decreased during the follow-up after exposure to ASA through the ASA-BPT in the AERD group (P < 0.05 for each, Fig. 1a, Table 2), but not in the ATA group (P > 0.05 for each, Table 2). The levels of serum SMs (d18:0/16:0, d18:0/18:1, d18:0/24:0, Lyso SM) showed positive correlations with methacholine-induced airway hyperreactivity (P = 0.051, P = 0.067, P = 0.033, P = 0.014, P = 0.071, P = 0.050 for each, Fig. 1b, Table 3). Regarding S1P, the levels in serum and urine samples were increased significantly following the ASA-BPT in both AERD and ATA groups (P < 0.05 for each, Table 2).

Figure 1. Changes in serum Sphingomyelin (SM) levels during the ASA-BPT in correlations with methacholine- induced airway hyperreactivity.

Figure 1

Open in a new tab

(a) Change in serum SM level following the ASA-BPT in the AERD group, (b) positive correlations of the serum SM levels at the basal status with PC20 to methacholine. Log-transformed data of PC20 to methacholine was analyzed.

Table 3. Association of baseline levels of serum SL metabolites with clinical features and biomarkers.

  serum S1P† Sphingosine† urine S1P† Urine Sphingosine† SM (d18:0/16:0)‡ SM (d18:0/18:0)‡ SM (d18:0/18:1)‡ SM (d18:0/24:0)‡ SM (d18:0/24:1)‡ Lyso SM‡
PC 20 (mg/mL)* −0.214 (0.075) −0.230(0.55) −0.111 (0.406) −0.211 (0.112) 0.251 (0.051) 0.236 (0.067) 0.273* (0.033) 0.314* (0.014) 0.233 (0.071) 0.252 (0.050)
Baseline FEV1 (% Pred) −0.033 (0.794) −0.029 (0.818) −0.048 (0.732) −0.103 (0.460) −0.114 (0.422) −0.020 (0.890) −0.033 (0.818) 0.023 (0.869) 0.095 (0.505) −0.062 (0.663)
% Fall (FEV1) 0.451*** (<0.001) 0.247 (0.053) 0.180 (0.207) 0.553*** (<0.001) −0.205 (0.152) −0.199 (0.166) −0.191 (0.183) −0.120 (0.406) −0.053 (0.716) −0.182 (0.205)
Serum 15-HETE (ng/ml) 0.152 (0.153) 0.459*** (<0.001) −0.124 (0.291) 0.006 (0.957) −0.338** (0.005) −0.299* (0.013) −0.263* (0.030) −0.197 (0.108) 0.001 (0.996) −0.282* (0.020)
Serum periostin (ng/ml) 0.233* (0.033) 0.237* (0.030) −0.102 (0.406) 0.405** (0.001) −0.146 (0.247) −0.115 (0.361) −0.121 (0.338) −0.102 (0.417) −0.051 (0.688) −0.101 (0.422)
Open in a new tab

†The data presented as Spearman’s rho correlation coefficient r (P value).

‡The data presented as Pearson correlation coefficient r (P value).

Serum S1P and urine sphingosine as potential biomarkers to differentiate AERD from ATA

The serum S1P and urine sphingosine levels were significantly higher in the AERD group than in the ATA group at the basal status, before the ASA-BPT, and at onset of reaction symptoms after the ASA, following the ASA-BPT (P < 0.001 for each, Fig. 2A).

Figure 2.

Figure 2

Open in a new tab

Comparison of the serum S1P and urine sphingosine levels (a) between the AERD and ATA groups, data are presented as means ± SD. Correlation of the basal status of serum S1P and urine sphingosine levels with (b) the decline of FEV1 (%) following the ASA-BPT, and (c) serum periostin level.

To assess the relationship between the SL metabolites and airway inflammation status, the correlation between the SL metabolites levels at the basal status before the ASA-BPT test and baseline clinical characteristics and biomarkers in asthmatic patients were evaluated (Table 3). The levels of serum S1P and urine sphingosine at the basal status before the ASA-BPT test were significantly correlated with a greater decrease in FEV1 (%) values during the ASA-BPT (r = 0.451, P < 0.001; r = 0.553, P < 0.001, respectively, Fig. 2B).

We investigated the correlation with serum periostin, which was known as a novel biomarker of AERD. At the basal status before the ASA-BPT test, the urine sphingosine level was positively correlated with the serum periostin level, however, the serum S1P showed a weak correlation with the basal status of serum periostin (r = 0.405, P = 0.001; r = 0.233, P = 0.033 respectively, Fig. 2C).

Using the ROC method, we evaluated the values of the serum S1P and urine sphingosine levels as diagnostic biomarkers for AERD (Fig. 3). To generate the highest levels of sensitivity and specificity, the optimal cut-off values from the ROC curve, a serum S1P > 93.5 ng/mL and urine sphingosine 33.5 pmol/mg Creatinine (pmol/mg Cr) was chosen. When these values were set, the serum S1P showed 72.2% sensitivity/71.1% specificity (AUC = 0.705, P = 0.002) and urine sphingosine showed 77.8% sensitivity/78.9% specificity, (AUC = 0.816, P < 0.001) for discriminating AERD from ATA.

Figure 3. ROC analysis for the basal status of serum S1P and urine sphingosine levels to predict AERD.

Figure 3

Open in a new tab

The continuous line represents urine sphingosine and the dashed line represents serum S1P.

We also examined the correlation between the SL metabolites at the basal status and 15-HETE which has been known to be as a diagnostic biomarker for AERD. The serum 15-HETE level was positively correlated with serum sphingosine (r = 0.459, P < 0.001, Table 3), while negatively correlated with serum SMs (d18:0/16:0, d18:0/18:0, d18:0/18:1, Lyso SM) (r = −0.338, P = 0.005; r = −0.299, P = 0.013, r = −0.263, P = 0.03; r = −0.282, P = 0.020 respectively, Table 3).

Correlation between the SL metabolites

Next, we assessed the correlation between the SL metabolites. The correlation coefficients between the SL metabolites are provided in Supplementary Tables E1 and E2. At the basal status before the ASA-BPT test, the serum S1P level was positively correlated with urine sphingosine level (r = 0.408, P < 0.001, Fig. 4, a1). After the onset of reaction symptoms following ASA-BPT, serum S1P level was correlated weakly with serum sphingosine level (r = 0.282, P = 0.007, Fig. 4, a2). The level of serum sphingosine at the basal status was negatively correlated with the level of serum SMs (d18:0/16:0, d18:0/18:0, d18:0/18:1, Lyso SM) (Fig. 4, b1–4, Table E1). The serum SM levels were positively correlated with the levels of ceramides (Table E1). The urine SM levels were positively correlated with the levels of urine ceramides (Table E2).

Figure 4. Correlation between the SL metabolite levels.

Figure 4

Open in a new tab

(a) Positive correlation of (a1) serum S1P and urine sphingosine at the basal status before the ASA-BPT, (a2) serum S1P and serum sphingosine at onset of reaction symptoms following the ASA-BPT. (b) Negative correlation of serum sphingosine level at the basal status with (b1) serum SM (d18:0/16:0), (b2) with serum SM (d18:0/18), (b3) with serum SM (d18:0/18:1), (b4) with serum LysoSM before the ASA-BPT.

Association of the urine sphingosine level with HLA-DBP1*0301 and CYSLTR1-634C > T polymorphism

We examined the association of S1P and sphingosine with HLA-DBP1*0301 and CYSLTR1-634C > T polymorphism in 89 asthmatic patients comprising of 44 patients with AERD and 45 with ATA (Table E3). In terms of HLA-DBP1*0301, patients with HLA-DBP*0301 alleles showed increased urine sphingosine levels at onset of reaction symptoms following the ASA-BPT compared to non-carriers (P = 0.012, Fig. 5a). In terms of CYSLTR1 −634C > T, patients with either heterozygous CT or homozygous TT genotypes demonstrated higher levels of urine sphingosine at the basal status before the ASA-BPT than those with the homozygous CC genotype (P = 0.042, Fig. 5b).

Figure 5.

Figure 5

Open in a new tab

Association of urine sphingosine level (a) at the basal status with HLA-DBP1*0301 and (b) at onset of reaction symptoms after the ASA-BPT test with CYSLTR1-634C > T polymorphism.

Discussion

AERD is well known as a distinct phenotype and endotype of asthma; it is characterized by eosinophilic inflammation, enhanced leukotriene production and activation of airway mast cells22,23. Recently, novel mechanisms have been proposed, such as systemic inflammation, aberrant functions of platelets and overexpressed platelet activation24,25,26. Aspirin challenge, for instance the ASA-BPT, is the gold standard for confirming aspirin hypersensitivity, however, there are still risks for bronchospasm as well as various contraindications27. In addition, no in vitro test has been routinely used for aspirin hypersensitivity despite the fact that AERD patients usually develop severe asthma and a higher frequency of emergency visits, hospitalizations and corticosteroid bursts15,16,17. Thus, non-invasive, serological tests should be investigated to determine an ideal biomarker for the AERD phenotype. In this study, we demonstrated the association of SL metabolites in AERD pathogenesis, especially serum S1P and urine sphingosine, could be potential biomarkers for AERD phenotype.

In the present study, we observed the metabolic disturbance of SL in AERD patients. By comparing changes in the SL metabolites following the ASA-BPT, we found a distorted pattern of ceramides and SMs after the ASA-BPT, with a decreased pattern in the AERD group (Fig. E1). In a pairwise comparison before and after the ASA-BPT in the AERD patients, the levels of serum SM (d18:0/18:0, d18:0/18:1, d18:0/24:0, d18:0/24:1) were significantly decreased following the ASA-BPT (Table 2, Fig. 1a). Furthermore, serum SM levels showed positive correlations with the concentration of methacholine needed to produce a 20% fall in FEV1 from baseline, PC20. This indicates that decreased SM levels in AERD patients associated with enhanced airway hyperreactivity. There are several reports supporting the relationship between SL and airway hyperreactivity. Worgall et al. demonstrated the association of impaired SL synthesis with airway hyperreacitivity by using de novo SPT inhibitor and an SPT knockout mouse model28. They found that impaired SPT activity induced decreased serum ceramides and sphingosine levels, finally resulting in bronchial hyperreactivity. The direct effect of S1P on airway hyperreactivity has been also reported; S1P administration increased airway reactivity in a dose – and time-dependent manner in mouse lungs, in which IL-17 may be involved10. In the present study, we firstly demonstrated the correlation of serum SM levels with methacholine-induced airway hyperreactivity.

The present study demonstrated the potential of serum S1P and urine sphingosine as biomarkers for identifying AERD. Enhanced levels of serum S1P, sphingosine and urine sphingosine were found in patients with AERD compared with those in ATA patients (Table 2, Fig. 2a). We also measured the serum S1P level in 29 healthy controls to validate the data and found a significantly increased level of serum S1P in AERD compared to healthy control groups (Fig. E2). In addition, the serum S1P and urine sphingosine levels were significantly correlated with a greater decrease in FEV1 (%) values after the ASA-BPT (Fig. 2b). Because the ASA-BPT has been validated and widely used in AERD diagnosis, these results indicate that the serum S1P and urine sphingosine levels are reliable, and safer markers to diagnose the AERD phenotype, without the fear of adverse reactions. We then confirmed the potential of serum S1P and urine sphingosine to differentiate AERD from ATA using ROC analysis, revealing that urine sphingosine is more optimal, with a relatively high sensitivity and specificity (Fig. 3).

Pezato et al.24 demonstrated the underlying systemic inflammation of AERD patients. AERD patients showed a differential baseline inflammatory pattern such as an enhanced baseline level of urine leukotriene E429. Similarly, the increased levels of S1P and sphingosine in the AERD patients showed positive correlations with the serum 15-HETE level, while the levels of serum SMs were negatively correlated with the serum 15-HETE level (Table 3). These findings demonstrate that alteration of SL metabolism (shifting SM into sphingosine and S1P) may be involved in the underlying mechanism of AERD. The SL metabolic pathway is an important cellular pathway that represents a highly coordinated system in which S1P induces cell survival, while ceramide induces programmed cell death2. According to previous knowledge of SL metabolism, the interconversion of SM into ceramide and S1P is under the control of anabolic and catabolic pathways, in which many kinases and phosphatases are involved, finally determining the cellular value of S1P. Together, S1P and sphingosine may participate in the systemic inflammatory response of AERD.

Next, we investigated the involvement of SLs in various aspects of AERD pathogenesis. Periostin has been suggested as a biomarker for disease severity in asthma as well as the best predictor of airway eosinophilia in asthmatics30. Periostin is necessary for house-dust mite-induced airway hyperresponsiveness in mice through dendritic cell activation31. A recent finding has demonstrated that serum periostin could also be used as a biomarker for the AERD phenotype and disease severity21. In our study, the serum S1P and urine sphingosine levels were positively correlated with the serum periostin level (Fig. 2c). Although the mechanisms of periostin in AERD are not fully understood, it is proposed that exposure to Th2-driven inflammation enhances the overexpression of the POSTN gene, resulting an increased level of periostin21. In addition, IL-13 may induce release of periostin from bronchial epithelial cells32. S1P is known to be associated with airway hyperactivity and Th2 cytokines in mouse lung10,11,33. S1P induction could lead to the release of Th2 cytokines, such as IL-4 and IL-1310,34. Therefore, we speculate that a high level of serum S1P in AERD could generate a Th2 cytokines-rich milieu for the production of periostin, subsequently contributing to more severe airway inflammatory responses.

The suggested genetic mechanisms of AERD are the polymorphisms of genes coding for CYSLTRs and the HLA system. HLA-DBP1*0301 has been proposed as an independent risk factor for the AERD phenotype19. The frequency of HLA-DPB1*0301 was more prominent in AERD patients than in ATA patients19. The AERD patients who have HLA-DBP1*0301 showed a higher requirement for leukotriene receptor antagonists for the management35. In addition, the polymorphism of CYSLTR1 at position -634 (C > T) is associated with the AERD phenotype20. The frequency of minor alleles of this SNP was higher in male AERD patients than in male ATA patients. Female patients with the CYSLTR1 -634CT or TT genotypes showed an increased total IgE level, perhaps resulting from the elevated production of the Th2 cytokine in this group20. Similarly, our study revealed that the urine sphingosine levels were increased in HLA-DPB1*0301 carriers and CYSLTR1 -634 (C > T) minor carriers (Fig. 5). The significance seems to be marginal due to limited number of study subjects, thus, further study in a large study cohort is needed to clarify the mechanistic basis regarding how the HLA-DPB1*0301 and CYSLTR1 gene polymorphisms can influence the level of the urine sphingosine.

Platelets contribute to the pathogenesis of AERD through various pathways, including the formation of platelet-leukocyte aggregates, abnormal function of platelets in vitro and overexpression of platelet activation25,26,36. After platelet activation, intracellular S1P is released into the environment37,38. In vitro studies have found that arachidonic acid could stimulate platelets to secrete S1P through the activation of the thromboxane receptor38. Recently, integrative pathway-based and conditional Gaussian Bayesian network analyses using multi-omics data have indicated that an altered SL metabolism represents an underlying feature of uncontrolled asthma and a therapeutic response to albuterol39. Interestingly, the S1P pathway was significantly enriched in the prostaglandin E2 expression signature; thirteen up-regulated and eight down-regulated genes in response to PGE2 treatment were determined to be part of the S1P pathway39. These findings may suggest a cross-talk between SL and eicosanoid metabolism in the pathogenesis of AERD in which platelet activation and subsequent platelet-leukocyte aggregates might be involved; however, further studies are required to elucidate the relationship between circulating S1P and the underlying systemic inflammation of AERD patients, as well as the downstream effects of S1P in AERD pathogenesis. Understanding the nature of SL metabolism and its pathological effect on the AERD phenotype would be useful in developing novel therapeutic strategies as well as early diagnostic tools.

In conclusion, to our knowledge, this study is the first to demonstrate that S1P and sphingosine are enhanced in AERD patients. SLs may play important roles in AERD pathogenesis. Serum S1P and urine sphingosine may be potential biomarkers for the AERD phenotype.

Materials and Methods

Study subjects and sample collection

We recruited 45 AERD and 45 ATA patients from the Ajou University Medical Center (Suwon, Korea) to investigate their SL metabolite profiles. All patients were evaluated for clinical history, chest radiography and pulmonary function tests. Subjects with stable asthma and a baseline FEV1 ≥ 50% predicted values underwent methacholine challenge in accordance with American Thoracic Society standards40. Subjects inhaled aerosolized normal saline, followed by aerosolized saline containing methacholine in doubling doses from 0.03 to 25.0 mg/mL. Methacholine was administered until either FEV1 fell by 20% of baseline or until the final dose was administered. If a subject experienced a drop in FEV1 from baseline of ≥ 20% before or immediately after the administration of the final dose, the test was considered positive40. For the ASA-BPT test, the patients were avoided the use of all anti-asthmatic drugs, including leukotriene modifiers, for at least 3 days before. The ASA-BPT was performed with increasing doses of ASA solution (up to 300 mg/mL) using previously described methods, and the tests were defined as positive when FEV1% decreased by more than 15% after the challenge41. The serum and urine samples were collected from the patients at different times; their basal statuses were examined before the ASA-BPT, and their onset of symptoms as well as FEV1 were examined after the ASA-BPT. For the ATA patients, the second sampling was performed 4 hours after the last dose of lysine-aspirin. We also recruited 29 normal healthy controls to validate the significant increase of serum S1P at the basal status before the ASA-BPT test (Supplementary Materials and Methods).

Serum total IgE was measured using the ImmunoCAP system (ThermoFisher Scientific, Uppsala, Sweden), and a range of 2–5000 kU/L. All of the subjects provided written informed consent and the study protocol was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-GEN-SMP-13–108), and all methods were performed in accordance with the relevant guidelines and regulations.

Quantification of SL metabolites

S1P and sphingosine in both serum and urine samples were quantified using the Mass Hunter Quantitative Analysis B.07.00 system (Agilent Technologies, Santa Clara, CA, USA). D-erythro-Sphingosine C-17 was used as the internal standard for sphingosine and S1P (Cayman Chemical., Ann Arbor, MI, USA). We also used Mass Hunter Quantitative Analysis B.07.00 to quantify the 15-HETE in which the deuterated internal standard 15-HETE-d8 (Cayman Chemical) was used. For the urine samples, creatinine was also quantified to normalize to the actual concentrations of each metabolite and 1,3-dimethyl-2-imidazolidinone (Sigma-Aldrich, St. Louis, MO, USA) was used as the internal standard for creatinine. The concentration of each metabolite was determined from calibration curves using linear regression analysis.

Ceramide and SMs were quantified through a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system equipped with 1290 HPLC (Agilent, Waldbronn, Germany) and QTRAP 5500 (AB Sciex, Toronto, Canada). Multiple reaction monitoring (MRM) was performed in the positive ion mode and the extracted ion chromatogram corresponding to the specific transition for each lipid was used for quantification. The calibration range for each lipid was 0.1–1,000 nM (r ≥ 0.99). Data analysis was performed using either Analyst 1.5.2 or Xcalibur software.

The limit of detection was determined as the lowest concentration that can still be detected and distinguished with the limit of blank.

Additional details of the methods used are available in the Methods section of this article’s online supplementary information.

Measurement of serum periostin levels

Serum periostin levels were measured with a proprietary sandwich ELISA (Shino-test, Kanagawa, Japan), as previously described21. ELISA was performed in duplicate. The reported limiting level of periostin for detection using this ELISA system is 100 pg/mL42.

Genotyping

Blood samples were collected from 89 asthmatic patients comprising AERD and ATA before the ASA-BPT test. Genomic DNA was isolated from the peripheral blood using the Puregene DNA purification kit (Gentra, Minneapolis, MN, USA), according to the manufacturer’s instructions.

High-resolution typing for HLA-DBP1*0301 was performed as previously described, using the amplified gene product of locus specific primers and direct sequencing with the ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA)19. Genotyping of CYSLTR1 -634C > T gene polymorphism (rs321029) was performed as previously described, using a primer extension method with a SNaPshot ddNTP primer extension kit (Applied Biosystems)20.

Statistical analysis

We log-transformed the data of methacholine concentration needed to produce a 20% fall in FEV1 and the serum total IgE level to correct their skewed distributions. Student’s t-test was used to compare continuous outcomes across the levels of each metabolite. General linear regression analysis was performed to adjust for confounding factors, sex and age, to compare the metabolite levels between the AERD and ATA patients. Paired t- test was used to compare paired continuous variables. Spearman’s rho correlation analysis identified the associations between continuous variables. To evaluate the diagnostic value of serum S1P and urine sphingosine for identifying AERD, a ROC analysis was used. All P values < 0.05 were considered to be statistically significant. Statistical analyses were performed using SPSS software version 20.0 (IBM Corp., Armonk, NY, USA). GraphPad Prism 5.0 software (GraphPad Inc., San Diego, CA, USA) was used to produce graphs.

Additional Information

How to cite this article: Trinh, H. K. T. et al. Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease. Sci. Rep. 6, 36599; doi: 10.1038/srep36599 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supplementary Information
srep36599-s1.doc (164.5KB, doc)

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No: 2015R1C1A2A01053492).

Footnotes

Author Contributions H.K.T.T. wrote the first draft of the manuscript. S.C.K. performed statistical analyses. K.S.C., S.J.K., H.J.Y. and J.Y.C. performed LC-MS experiments. G.Y.B. contributed to recruitment of study subjects and collection of clinical data. H.S.P. contributed to the design of the study, recruitment of study subjects and collection of clinical data. S.H.K. contributed to the design of the study, supervision of the study, data analysis and interpretation, the preparation of the manuscript and the revision.

References

  1. Harvald E. B., Olsen A. S. & Faergeman N. J. Autophagy in the light of sphingolipid metabolism. Apoptosis. 20, 658–670 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Pralhada Rao R. et al. Sphingolipid metabolic pathway: an overview of major roles played in human diseases. J Lipids. 2013, 178910 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gault C. R., Obeid L. M. & Hannun Y. A. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 688, 1–23 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ryan J. J. & Spiegel S. The role of sphingosine-1-phosphate and its receptors in asthma. Drug News Perspect. 21, 89–96 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Yang Y. & Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 5, 325–344 (2011). [DOI] [PubMed] [Google Scholar]
  6. Worgall T. S. et al. Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity. Sci Transl Med. 5, 186ra167–186ra167 (2013). [DOI] [PubMed] [Google Scholar]
  7. Scarpa M. C. et al. Ceramide expression and cell homeostasis in chronic obstructive pulmonary disease. Respiration 85, 342–349 (2013). [DOI] [PubMed] [Google Scholar]
  8. Oskeritzian C. A. et al. The sphingosine-1-phosphate/sphingosine-1-phosphate receptor 2 axis regulates early airway T-cell infiltration in murine mast cell-dependent acute allergic responses. J Allergy Clin Immunol. 135, 1008–1018 e1001 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jolly P. S. et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med. 199, 959–970 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Roviezzo F. et al. Systemic administration of sphingosine-1-phosphate increases bronchial hyperresponsiveness in the mouse. Am J Respir Cell Mol Biol. 42, 572–577 (2010). [DOI] [PubMed] [Google Scholar]
  11. Roviezzo F. et al. S1P-induced airway smooth muscle hyperresponsiveness and lung inflammation in vivo: molecular and cellular mechanisms. Br J Pharmacol. 172, 1882–1893 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fuerst E. et al. Sphingosine-1-phosphate induces pro-remodelling response in airway smooth muscle cells. Allergy 69, 1531–1539 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fanta C. H. Asthma. N Eng J Med. 360, 1002–1014 (2009). [DOI] [PubMed] [Google Scholar]
  14. Lötvall J. et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 127, 355–360 (2011). [DOI] [PubMed] [Google Scholar]
  15. Moon J. Y. et al. Aspirin-intolerant asthma in the Korean population: prevalence and characteristics based on a questionnaire survey. Respir Med. 107, 202–208 (2013). [DOI] [PubMed] [Google Scholar]
  16. Eriksson J. et al. Aspirin-intolerant asthma in the population: prevalence and important determinants. Clin Exp Allergy. 45, 211–219 (2015). [DOI] [PubMed] [Google Scholar]
  17. Peters S. P., Ferguson G., Deniz Y. & Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 100, 1139–1151 (2006). [DOI] [PubMed] [Google Scholar]
  18. James A. et al. The influence of aspirin on release of eoxin C4, leukotriene C4 and 15-HETE, in eosinophilic granulocytes isolated from patients with asthma. Int Arch Allergy Immunol. 162, 135–142 (2013). [DOI] [PubMed] [Google Scholar]
  19. Choi J. H. et al. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J Allergy Clin Immunol. 113, 562–564 (2004). [DOI] [PubMed] [Google Scholar]
  20. Kim S. H. et al. CysLTR1 promoter polymorphism and requirement for leukotriene receptor antagonist in aspirin-intolerant asthma patients. Pharmacogenomics 8, 1143–1150 (2007). [DOI] [PubMed] [Google Scholar]
  21. Kim M. A. et al. Association of serum periostin with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 113, 314–320 (2014). [DOI] [PubMed] [Google Scholar]
  22. Laidlaw T. M. & Boyce J. A. Aspirin-Exacerbated Respiratory Disease–New Prime Suspects. N Engl J Med. 374, 484–488 (2016). [DOI] [PubMed] [Google Scholar]
  23. Liu T. et al. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway. J Immunol. 195, 3537–3545 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pezato R. et al. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease. Cytokine 77, 157–167 (2016). [DOI] [PubMed] [Google Scholar]
  25. Laidlaw T. M. & Boyce J. A. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 135, 1407–1414 quiz 1415 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mitsui C. et al. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 137, 400–411 (2016). [DOI] [PubMed] [Google Scholar]
  27. Garcia Cruz M. L., Jimenez-Chobillon M. A. & Teran L. M. Rhinosinusitis and aspirin-exacerbated respiratory disease. J Allergy (Cairo) 2012, 273752 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Worgall T. S. et al. Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity. Sci Trans Med. 5, 186ra167 (2013). [DOI] [PubMed] [Google Scholar]
  29. Celejewska-Wojcik N. et al. Incidence of aspirin hypersensitivity in patients with chronic rhinosinusitis and diagnostic value of urinary leukotriene E4. Pol Arch Med Wewn. 122, 422–427 (2012). [DOI] [PubMed] [Google Scholar]
  30. Jia G. et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 130, 647–654 e610 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Bentley J. K. et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice. J Allergy Clin Immunol. 134, 1433–1442 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Agrawal S. & Townley R. G. Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma. Expert Opin Biol Ther. 14, 165–181 (2014). [DOI] [PubMed] [Google Scholar]
  33. Trifilieff A. & Fozard J. R. Sphingosine-1-phosphate-induced airway hyper-reactivity in rodents is mediated by the sphingosine-1-phosphate type 3 receptor. J Pharmacol Exp Ther. 342, 399–406 (2012). [DOI] [PubMed] [Google Scholar]
  34. Idzko M. et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J. 16, 625–627 (2002). [DOI] [PubMed] [Google Scholar]
  35. Park H. S., Kim S. H., Sampson A. P., Lee K. W. & Park C. S. The HLA-DPB1*0301 marker might predict the requirement for leukotriene receptor antagonist in patients with aspirin-intolerant asthma. J Allergy Clin Immunol. 114, 688–689 (2004). [DOI] [PubMed] [Google Scholar]
  36. Laidlaw T. M. et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 119, 3790–3798 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Munzer P. et al. Sphingosine kinase 1 (Sphk1) negatively regulates platelet activation and thrombus formation. Am J Physiol Cell Physiol. 307, C920–C927 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ulrych T. et al. Release of sphingosine‐1‐phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost. 9, 790–798 (2011). [DOI] [PubMed] [Google Scholar]
  39. McGeachie M. J. et al. The metabolomics of asthma control: a promising link between genetics and disease. Immun Inflamm Dis. 3, 224–238 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Crapo R. O. et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 161, 309–329 (2000). [DOI] [PubMed] [Google Scholar]
  41. Park H. S. Early and late onset asthmatic responses following lysine-aspirin inhalation in aspirin-sensitive asthmatic patients. Clin Exp Allergy. 25, 38–40 (1995). [DOI] [PubMed] [Google Scholar]
  42. Okamoto M. et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 37, 1119–1127 (2011). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep36599-s1.doc (164.5KB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES